1 Report Business Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 1.2.2 Intravenous 1.2.3 Oral 1.2.4 Subcutaneous 1.2.5 Others 1.3 Market by Application 1.3.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Perspective (2017-2028) 2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Growth Trends by Region 2.2.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Region (2017-2022) 2.2.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Region (2023-2028) 2.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Dynamics 2.3.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Industry Trends 2.3.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers 2.3.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Challenges 2.3.4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Revenue 3.1.1 Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Revenue (2017-2022) 3.1.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Players (2017-2022) 3.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue 3.4 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration Ratio 3.4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in 2021 3.5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Key Players Head office and Area Served 3.6 Key Players Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Solution and Service 3.7 Date of Enter into Neuromyelitis Optica Spectrum Disorder (NMOSD) Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Breakdown Data by Type 4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Type (2017-2022) 4.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Type (2023-2028) 5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Breakdown Data by Application 5.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Application (2017-2022) 5.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2017-2028) 6.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type 6.2.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2017-2022) 6.2.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2023-2028) 6.2.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2017-2028) 6.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application 6.3.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2017-2022) 6.3.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2023-2028) 6.3.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2017-2028) 6.4 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country 6.4.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2017-2022) 6.4.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2023-2028) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2017-2028) 7.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type 7.2.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2017-2022) 7.2.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2023-2028) 7.2.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2017-2028) 7.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application 7.3.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2017-2022) 7.3.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2023-2028) 7.3.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2017-2028) 7.4 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country 7.4.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2017-2022) 7.4.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2023-2028) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2017-2028) 8.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type 8.2.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2017-2022) 8.2.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2023-2028) 8.2.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2017-2028) 8.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application 8.3.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2017-2022) 8.3.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2023-2028) 8.3.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2017-2028) 8.4 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region 8.4.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2017-2022) 8.4.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2023-2028) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2017-2028) 9.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type 9.2.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2017-2022) 9.2.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2023-2028) 9.2.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2017-2028) 9.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application 9.3.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2017-2022) 9.3.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2023-2028) 9.3.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2017-2028) 9.4 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country 9.4.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2017-2022) 9.4.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2023-2028) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2017-2028) 10.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type 10.2.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2017-2022) 10.2.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2023-2028) 10.2.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2017-2028) 10.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application 10.3.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2017-2022) 10.3.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2023-2028) 10.3.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2017-2028) 10.4 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country 10.4.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2017-2022) 10.4.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2023-2028) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 F. Hoffmann-La Roche Ltd 11.1.1 F. Hoffmann-La Roche Ltd Company Details 11.1.2 F. Hoffmann-La Roche Ltd Business Overview 11.1.3 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction 11.1.4 F. Hoffmann-La Roche Ltd Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) 11.1.5 F. Hoffmann-La Roche Ltd Recent Developments 11.2 Alexion Pharmaceuticals 11.2.1 Alexion Pharmaceuticals Company Details 11.2.2 Alexion Pharmaceuticals Business Overview 11.2.3 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction 11.2.4 Alexion Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) 11.2.5 Alexion Pharmaceuticals Recent Developments 11.3 RemeGen 11.3.1 RemeGen Company Details 11.3.2 RemeGen Business Overview 11.3.3 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction 11.3.4 RemeGen Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) 11.3.5 RemeGen Recent Developments 11.4 Nihon Pharmaceutical 11.4.1 Nihon Pharmaceutical Company Details 11.4.2 Nihon Pharmaceutical Business Overview 11.4.3 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction 11.4.4 Nihon Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) 11.4.5 Nihon Pharmaceutical Recent Developments 11.5 Harbour BioMed 11.5.1 Harbour BioMed Company Details 11.5.2 Harbour BioMed Business Overview 11.5.3 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction 11.5.4 Harbour BioMed Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) 11.5.5 Harbour BioMed Recent Developments 11.6 Lundbeck 11.6.1 Lundbeck Company Details 11.6.2 Lundbeck Business Overview 11.6.3 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction 11.6.4 Lundbeck Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) 11.6.5 Lundbeck Recent Developments 11.7 Bionure 11.7.1 Bionure Company Details 11.7.2 Bionure Business Overview 11.7.3 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction 11.7.4 Bionure Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) 11.7.5 Bionure Recent Developments 11.8 Opexa Therapeutics 11.8.1 Opexa Therapeutics Company Details 11.8.2 Opexa Therapeutics Business Overview 11.8.3 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction 11.8.4 Opexa Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) 11.8.5 Opexa Therapeutics Recent Developments 11.9 TG Therapeutics 11.9.1 TG Therapeutics Company Details 11.9.2 TG Therapeutics Business Overview 11.9.3 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction 11.9.4 TG Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) 11.9.5 TG Therapeutics Recent Developments 11.10 Bio-Thera Solutions 11.10.1 Bio-Thera Solutions Company Details 11.10.2 Bio-Thera Solutions Business Overview 11.10.3 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction 11.10.4 Bio-Thera Solutions Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) 11.10.5 Bio-Thera Solutions Recent Developments 11.11 Boston Pharmaceuticals 11.11.1 Boston Pharmaceuticals Company Details 11.11.2 Boston Pharmaceuticals Business Overview 11.11.3 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction 11.11.4 Boston Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) 11.11.5 Boston Pharmaceuticals Recent Developments 11.12 Cour Pharmaceutical 11.12.1 Cour Pharmaceutical Company Details 11.12.2 Cour Pharmaceutical Business Overview 11.12.3 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction 11.12.4 Cour Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) 11.12.5 Cour Pharmaceutical Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Author Details 13.3 Disclaimer

List of Tables Table 1. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028 Table 2. Key Players of Intravenous Table 3. Key Players of Oral Table 4. Key Players of Subcutaneous Table 5. Key Players of Others Table 6. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028 Table 7. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 8. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2017-2022) & (US$ Million) Table 9. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Region (2017-2022) Table 10. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 11. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Region (2023-2028) Table 12. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Trends Table 13. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers Table 14. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Challenges Table 15. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints Table 16. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue by Players (2017-2022) & (US$ Million) Table 17. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Share by Players (2017-2022) Table 18. Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) as of 2021) Table 19. Ranking of Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies by Revenue (US$ Million) in 2021 Table 20. Global 5 Largest Players Market Share by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (CR5 and HHI) & (2017-2022) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Solution and Service Table 23. Date of Enter into Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2017-2022) & (US$ Million) Table 26. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2017-2022) Table 27. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 28. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2023-2028) Table 29. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2017-2022) & (US$ Million) Table 30. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Share by Application (2017-2022) Table 31. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 32. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Share by Application (2023-2028) Table 33. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2017-2022) & (US$ Million) Table 34. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2023-2028) & (US$ Million) Table 35. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2017-2022) & (US$ Million) Table 36. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2023-2028) & (US$ Million) Table 37. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2017-2022) & (US$ Million) Table 38. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2023-2028) & (US$ Million) Table 39. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2017-2022) & (US$ Million) Table 40. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2023-2028) & (US$ Million) Table 41. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2017-2022) & (US$ Million) Table 42. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2023-2028) & (US$ Million) Table 43. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2017-2022) & (US$ Million) Table 44. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2023-2028) & (US$ Million) Table 45. Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2017-2022) & (US$ Million) Table 46. Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2023-2028) & (US$ Million) Table 47. Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2017-2022) & (US$ Million) Table 48. Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2023-2028) & (US$ Million) Table 49. Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2017-2022) & (US$ Million) Table 50. Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2023-2028) & (US$ Million) Table 51. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2017-2022) & (US$ Million) Table 52. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2023-2028) & (US$ Million) Table 53. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2017-2022) & (US$ Million) Table 54. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2023-2028) & (US$ Million) Table 55. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2017-2022) & (US$ Million) Table 56. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2023-2028) & (US$ Million) Table 57. Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2017-2022) & (US$ Million) Table 58. Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2023-2028) & (US$ Million) Table 59. Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2017-2022) & (US$ Million) Table 60. Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2023-2028) & (US$ Million) Table 61. Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2017-2022) & (US$ Million) Table 62. Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2023-2028) & (US$ Million) Table 63. F. Hoffmann-La Roche Ltd Company Details Table 64. F. Hoffmann-La Roche Ltd Business Overview Table 65. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Table 66. F. Hoffmann-La Roche Ltd Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) & (US$ Million) Table 67. F. Hoffmann-La Roche Ltd Recent Developments Table 68. Alexion Pharmaceuticals Company Details Table 69. Alexion Pharmaceuticals Business Overview Table 70. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Table 71. Alexion Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) & (US$ Million) Table 72. Alexion Pharmaceuticals Recent Developments Table 73. RemeGen Company Details Table 74. RemeGen Business Overview Table 75. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Table 76. RemeGen Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) & (US$ Million) Table 77. RemeGen Recent Developments Table 78. Nihon Pharmaceutical Company Details Table 79. Nihon Pharmaceutical Business Overview Table 80. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Table 81. Nihon Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) & (US$ Million) Table 82. Nihon Pharmaceutical Recent Developments Table 83. Harbour BioMed Company Details Table 84. Harbour BioMed Business Overview Table 85. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Table 86. Harbour BioMed Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) & (US$ Million) Table 87. Harbour BioMed Recent Developments Table 88. Lundbeck Company Details Table 89. Lundbeck Business Overview Table 90. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Table 91. Lundbeck Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) & (US$ Million) Table 92. Lundbeck Recent Developments Table 93. Bionure Company Details Table 94. Bionure Business Overview Table 95. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Table 96. Bionure Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) & (US$ Million) Table 97. Bionure Recent Developments Table 98. Opexa Therapeutics Company Details Table 99. Opexa Therapeutics Business Overview Table 100. Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Table 101. Opexa Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) & (US$ Million) Table 102. Opexa Therapeutics Recent Developments Table 103. TG Therapeutics Company Details Table 104. TG Therapeutics Business Overview Table 105. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Table 106. TG Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) & (US$ Million) Table 107. TG Therapeutics Recent Developments Table 108. Bio-Thera Solutions Company Details Table 109. Bio-Thera Solutions Business Overview Table 110. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Table 111. Bio-Thera Solutions Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) & (US$ Million) Table 112. Bio-Thera Solutions Recent Developments Table 113. Boston Pharmaceuticals Company Details Table 114. Boston Pharmaceuticals Business Overview Table 115. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Table 116. Boston Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) & (US$ Million) Table 117. Boston Pharmaceuticals Recent Developments Table 118. Cour Pharmaceutical Company Details Table 119. Cour Pharmaceutical Business Overview Table 120. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Table 121. Cour Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) & (US$ Million) Table 122. Cour Pharmaceutical Recent Developments Table 123. Research Programs/Design for This Report Table 124. Key Data Information from Secondary Sources Table 125. Key Data Information from Primary Sources List of Figures Figure 1. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type: 2021 VS 2028 Figure 2. Intravenous Features Figure 3. Oral Features Figure 4. Subcutaneous Features Figure 5. Others Features Figure 6. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application: 2021 VS 2028 Figure 7. Hospital Case Studies Figure 8. Clinic Case Studies Figure 9. Others Case Studies Figure 10. Neuromyelitis Optica Spectrum Disorder (NMOSD) Report Years Considered Figure 11. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 12. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 13. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Region: 2021 VS 2028 Figure 14. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Players in 2021 Figure 15. Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) as of 2021) Figure 16. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in 2021 Figure 17. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY (2017-2028) & (US$ Million) Figure 18. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Market Share by Type (2017-2028) Figure 19. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Market Share by Application (2017-2028) Figure 20. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Share by Country (2017-2028) Figure 21. United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 22. Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY (2017-2028) & (US$ Million) Figure 24. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Market Share by Type (2017-2028) Figure 25. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Market Share by Application (2017-2028) Figure 26. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Share by Country (2017-2028) Figure 27. Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. France Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. U.K. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. Nordic Countries Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY (2017-2028) & (US$ Million) Figure 34. Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Market Share by Type (2017-2028) Figure 35. Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Market Share by Application (2017-2028) Figure 36. Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Share by Region (2017-2028) Figure 37. China Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. Southeast Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. India Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) List of Figures Figure 43. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY (2017-2028) & (US$ Million) Figure 44. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Market Share by Type (2017-2028) Figure 45. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Market Share by Application (2017-2028) Figure 46. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Share by Country (2017-2028) Figure 47. Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 48. Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 49. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY (2017-2028) & (US$ Million) Figure 50. Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Market Share by Type (2017-2028) Figure 51. Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Market Share by Application (2017-2028) Figure 52. Middle East and Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Share by Country (2017-2028) Figure 53. Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 54. Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 55. UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 56. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) Figure 57. Alexion Pharmaceuticals Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) Figure 58. RemeGen Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) Figure 59. Nihon Pharmaceutical Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) Figure 60. Harbour BioMed Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) Figure 61. Lundbeck Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) Figure 62. Bionure Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) Figure 63. Opexa Therapeutics Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) Figure 64. TG Therapeutics Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) Figure 65. Bio-Thera Solutions Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) Figure 66. Boston Pharmaceuticals Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) Figure 67. Cour Pharmaceutical Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022) Figure 68. Bottom-up and Top-down Approaches for This Report Figure 69. Data Triangulation Figure 70. Key Executives Interviewed

F. Hoffmann-La Roche Ltd Alexion Pharmaceuticals RemeGen Nihon Pharmaceutical Harbour BioMed Lundbeck Bionure Opexa Therapeutics TG Therapeutics Bio-Thera Solutions Boston Pharmaceuticals Cour Pharmaceutical